Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF.

ABSTRACT:

Abstract

Postpartum hemorrhage (PPH) affects up to 44% of women with von Willebrand disease (VWD) despite von Willebrand factor (VWF) replacement. Because tranexamic acid (TXA) reduced PPH-related deaths in the WOMAN trial, we assessed whether TXA combined with rVWF vs rVWF alone prevents PPH in VWD. VWD-Woman, a phase 3, open-label, randomized pilot trial, enrolled pregnant women with VWD, aged ≥18 years (von Willebrand Factor Ristocetin Cofactor activity [VWF:RCo] of <0.50 IU/mL, bleeding history). Participants received IV rVWF 80 IU/kg at delivery and postpartum days 1 and 2, with or without TXA (1 g within 3 hours of delivery). The primary outcome was quantitative blood loss (QBL) at delivery. Secondary outcomes included 21-day pictorial blood assessment chart (PBAC) scores, he

SUBMITTER: Machin NC 

PROVIDER: S-EPMC12686688 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature